| Identification | Back Directory | [Name]
9-Hexadecenoic acid, 2-[[2-[[9,10-dihydro-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-dioxo-1-anthracenyl]amino]ethyl]amino]ethyl ester, (9Z)- | [CAS]
1349197-89-2 | [Synonyms]
mono-Pal-MTO
9-Hexadecenoic acid, 2-[[2-[[9,10-dihydro-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-dioxo-1-anthracenyl]amino]ethyl]amino]ethyl ester, (9Z)- | [Molecular Formula]
C38H56N4O7 | [MOL File]
1349197-89-2.mol | [Molecular Weight]
680.87 |
| Hazard Information | Back Directory | [Uses]
mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1]. | [References]
[1] Rae Sung Chang, et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials. 2011 Dec;32(36):9785-95. DOI:10.1016/j.biomaterials.2011.09.017 |
|
|